FDA Removes Clinical Hold on BioCryst's BCX 4161 -8K; Pacira Announces EXPAREL Phase 3 Trial Does Not Meet Primary Endpoint Print E-mail
By Staff and Wire Reports   
Thursday, 01 August 2013 19:34
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 1, 2013.
Read more...
 
Discounted Price Levels Make CEL-SCI Shares A Solid Speculative “Buy” Bet Print E-mail
By Ray Dirks of Ray Dirks Research   
Thursday, 01 August 2013 05:54
icon_bottombouncerWith shares trading at heavily discounted price levels, speculative investors looking for a good bottom bounce trade should have their sights set on CEL-SCI Corporation (AMEX: CVM) who last provided investors a much needed update on their Phase III Clinical Trial of its investigational head and neck cancer drug Multikine in late April.
Read more...
 
Sanofi Announces FDA Panel Recommends Approval of Nasacort; Integra Receives FDA Clearance for Titan(TM) Print E-mail
By Staff and Wire Reports   
Wednesday, 31 July 2013 19:43
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 31, 2013.
Read more...
 
Alexza Reports European Launch of ADASUVE; Abbott Announces New Data on High-Sensitive Troponin Test Print E-mail
By Staff and Wire Reports   
Tuesday, 30 July 2013 18:43
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 30, 2013.
Read more...
 
Biodel Expecting To Release Top-Line Data Soon As Investors Take Notice Print E-mail
By Scott Matusow   
Tuesday, 30 July 2013 10:33
Going long ahead of certain biopharma catalysts have proven to be a very sucessfull trade this year, especially with small cap biopharmas, as  many small cap companies have seen large upside moves.
Read more...
 
Significant Catalyst Should Further Rally Keryx Pharmaceuticals Print E-mail
By Scott Matusow   
Wednesday, 24 July 2013 07:48
Recently, we have detailed companies that have released positive Phase III data because we believe several of these companies continue to be under speculation value.
Read more...
 
Biogen – Ahead of Q2 Earnings on Thursday Print E-mail
By Brian Wilson-Lead Contributor   
Tuesday, 23 July 2013 12:12
Despite continuing strength in the biotech sector, Biogen Idec (NASDAQ: BIIB) has been unable to attain new highs due to the excessive hype over the
commercialization potential of new multiple sclerosis drug Tecfidera (dimethyl fumarate) earlier in the year.
Read more...
 
Q&A with Coronado Biosciences CEO Harlan Weisman, M.D. Print E-mail
By Staff and Wire Reports   
Tuesday, 23 July 2013 01:27
It has been over a year since we last discussed Coronado Biosciences (NASDAQ:CNDO), and the

Error. Page cannot be displayed. Please contact your service provider for more details. (24)

company, so we thought it time for an updated Q&A with the management of one of biotech's most talked about plays.
Read more...
 
Updates on 3 Heavily-Watched Companies With Recent Launches Print E-mail
By Brian Wilson - Lead Contributor   
Monday, 22 July 2013 11:46
Amarin (NASDAQ: AMRN) is continuing to commercialize Vascepa – their omega-3 pill which contains over 95% eicosapentaenoic acid.
Read more...
 
Merger And Acquisition Watch Solta Medical Will Be Acquired Soon Here Is Why Print E-mail
By Scott Matusow   
Sunday, 21 July 2013 22:12
In August of 2012, I wrote an article detailing why Obagi Medical Products would be acquired soon. Obagi was under pressure from Voce Capital Management to sell the company.
Read more...
 
<< Start < Prev 21 22 23 24 25 26 27 28 29 30 Next > End >>

Page 26 of 55
BMR:1